AngioDynamics, Inc. (NASDAQ:ANGO) Q4 2023 Earnings Conference Call July 12, 2023 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants Jason Bedford - Raymond James Bill Plovanic - Canaccord Genuity Matthew Mishan - KeyBanc Capital Markets Operator Good morning, and welcome to the AngioDynamics Fourth Quarter and Fiscal Year 2023 Earnings Call. At this time, all participants are ...

1 ANGIODYNAMICS Fourth Quarter 2023 Earnings Presentation July 12, 2023 Forward-Looking Statement Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans an ...

ANGIODYNAMICS Third Quarter 2023 Earnings Presentation March 30, 2023 1 Forward-Looking Statement Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans an ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |--------------------------------------------------------------------------------------------| | For the transition period from to Commission file number 0-50761 | | Angio ...

AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2023 Earnings Call Transcript March 30, 2023 8:00 AM ET Company Participants Jim Clemmer - CEO Steve Trowbridge - CFO Conference Call Participants Brett Fishbin - KeyBanc Steven Lichtman - Oppenheimer Jayson Bedford - Raymond James Bill Plovanic - Canaccord Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2023 Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal pres ...

Raymond James 44th Annual Institutional Investors Conference March 6, 2023 Jim Clemmer, President & CEO Stephen Trowbridge, Executive Vice President & CFO Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, produ ...

ANGIODYNAMICS Second Quarter 2023 Earnings Presentation January 5, 2023 1 Forward-Looking Statement Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans ...

AngioDynamics, Inc. (NASDAQ:ANGO) Q2 2023 Earnings Conference Call January 5, 2023 8:00 AM ET Company Participants Jim Clemmer - President and CEO Steve Trowbridge - Executive Vice President and CFO Conference Call Participants Jayson Bedford - Raymond James Bill Plovanic - Canaccord Genuity Steve Lichtman - Oppenheimer Matthew Mishan - KeyBanc Capital Markets Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2023 Second Quarter Earnings Call. At this time all participants are in listen-on ...

Financial Performance - Net sales for the three months ended November 30, 2022, were $85,429 thousand, an increase of 9.3% compared to $78,280 thousand for the same period in 2021[19] - Gross profit for the six months ended November 30, 2022, was $87,383 thousand, up from $80,694 thousand for the same period in 2021, reflecting a gross margin improvement[19] - Operating loss for the three months ended November 30, 2022, was $(8,115) thousand, slightly improved from $(8,679) thousand in the prior year[19] - Net loss for the six months ended November 30, 2022, was $(21,490) thousand, compared to $(15,323) thousand for the same period in 2021, indicating a worsening financial performance[21] - The net loss for the three months ended November 30, 2022, was $8.5 million, consistent with a loss per share of $0.21[130] - The net loss for the six months ended November 30, 2022, increased by $6.2 million to $21.5 million, with a loss per share of $0.55[127] Cash and Assets - Cash and cash equivalents at the end of the period were $29,857 thousand, an increase from $28,825 thousand at the beginning of the period[28] - Total assets as of November 30, 2022, were $558,207 thousand, a slight increase from $552,751 thousand as of May 31, 2022[25] - The company had total debt outstanding of $50.0 million as of November 30, 2022, related to the Credit Agreement[149] - Cash used in operating activities was $17.2 million for the six months ended November 30, 2022, compared to $7.0 million for the same period in the prior year[150] Debt and Liabilities - Long-term debt increased to $49,796 thousand from $25,000 thousand, indicating a significant rise in leverage[25] - The company entered into a new Credit Agreement providing for a $75.0 million secured revolving credit facility and a $30.0 million delayed draw term loan[67] - As of November 30, 2022, the company had $25.0 million outstanding on the Revolving Facility and $25.0 million on the Delayed Draw Term Loan, with an interest rate of 5.59%[70] - The total lease liabilities decreased from $7,263,000 on May 31, 2022, to $5,981,000 on November 30, 2022, indicating a reduction in lease obligations[95] Revenue Segments - The Med Tech segment generated $24,502,000 in net sales for the three months ended November 30, 2022, compared to $18,886,000 in the prior year, indicating a growth of 30%[43] - The Med Device segment reported net sales of $60,927,000 for the three months ended November 30, 2022, up from $59,394,000 in the same period of 2021, reflecting a growth of 3%[43] - Med Tech segment net sales increased by $5.6 million for the three months and $10.8 million for the six months ended November 30, 2022, primarily driven by increased Auryon sales[134] - Med Device segment net sales increased by $1.5 million for the three months and $0.9 million for the six months ended November 30, 2022, despite backlog impacts[135] Expenses - Research and development expenses for the three months ended November 30, 2022, were $6,838 thousand, down from $8,199 thousand in the prior year, reflecting cost management efforts[19] - Share-based compensation expense for the six months ended November 30, 2022, was $6,400,000, compared to $5,400,000 for the same period in 2021, reflecting an increase of 18.5%[77] - Sales and marketing expense increased by $2.4 million and $4.5 million for the three and six months ended November 30, 2022, compared to the same periods in the prior year[141] - General and administrative expense increased by $1.2 million and $2.3 million for the three and six months ended November 30, 2022, compared to the same periods in the prior year[142] Stockholder Equity - Total stockholders' equity decreased to $407,958 thousand as of November 30, 2022, from $424,489 thousand as of May 31, 2022, indicating a decline in shareholder value[26] - The total balance of treasury stock was $407,958,000, with a net loss of $8,486,000 recorded during the period[31] - The total balance of treasury stock increased from $424,489,000 on May 31, 2022, to $414,041,000 by August 31, 2022[31] Legal and Compliance - The company is involved in various legal proceedings, but has not recorded an expense related to the outcome of ongoing litigation as it cannot determine if a potential loss is probable or reasonably estimable[101] - The company reported legal expenses of $2,422,000 for the three months ended November 30, 2022, compared to $2,072,000 for the same period in 2021, reflecting an increase of 16.9%[108] - The company has not recorded an expense related to ongoing litigation as it is not yet possible to determine if a potential loss is probable nor reasonably estimable[104] Market and Strategic Focus - The company is focused on transforming its portfolio to target larger and faster-growing markets, which is expected to drive near to mid-term growth[41] - The company aims to grow sales and profitability by expanding geographically and introducing new products, with a focus on research and development investments[123] - The company’s business operations are influenced by market dynamics such as value-based purchasing, healthcare provider consolidation, and an aging population[122] Tax and Valuation - The estimated annual effective tax rate prior to discrete items was 5.8% for the second quarter of fiscal year 2023, down from 12.3% for the same period in fiscal year 2022[72] - The Company has provided a valuation allowance on its deferred tax assets due to not attaining a sustained level of profitability as of November 30, 2022[74]